You are here

Developing Inhibitors of the STARS/SRF Pathway for Treatment of Type 2 Diabetes

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK096772-01A1
Agency Tracking Number: R41DK096772
Amount: $150,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDDK
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BOSTON, MA 02215-5306
United States
DUNS: 967822276
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (617) 309-4302
Business Contact
Phone: (617) 309-4302
Research Institution
BOSTON, MA 02215-5306
United States

 () -
 Domestic nonprofit research organization

DESCRIPTION (provided by applicant): Type 2 diabetes (T2D) has reached epidemic proportions in the United States, affecting an estimated 8.3% of the population. Unfortunately, the majority of individuals with diabetes continue to have suboptimal control ofglucose, therefore new and improved approaches to prevention and treatment are sorely needed. Dr. Mary Elizabeth Patti's laboratory at the Joslin Diabetes Center (JDC) has recently identified a novel pattern of gene expression in skeletal muscle from human patients with established T2D. This pattern includes increased expression of genes regulated by serum response factor (SRF) and its upstream regulatory protein STARS (striated muscle activator of Rho-dependent signaling). Importantly, this pattern is also present in those at risk for disease based on family history, potentially linking this to T2D-risk. Genetic and pharmacologic data from the Patti lab (JDC) robustly indicate that modulation of the STARS-SRF pathway can regulate muscle insulin resist

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government